News & Updates
Excerpt from the Article: PHILADELPHIA—An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn’s Perelman School of Medicine. The findings suggest that the Penn-developed tool…
Read More
Excerpt from the Press Release: PRINCETON, N.J., June 03, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF™) Gene Therapy…
Read More
Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 28, 2021 / CureVac N.V. (NASDAQ:CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD)…
Read More
Excerpt from the Press Release: BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ — SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes…
Read More
Excerpt from the Press Release: LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s…
Read More
Excerpt from the Article: When it comes to designing and building novel medical devices to meet the needs of patients and healthcare systems, developers should rely on the core skills of engineering and design to inform their process. But there are “lessons learned” that are unique to the medical device development process. The team at Goddard has…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV)…
Read More
Excerpt from the Press Release: BOSTON and MONTRÉAL, May 27, 2021 /PRNewswire/ – enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle…
Read More
Excerpt from the Announcement: The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that would attract partnerships and/or investment for further preclinical and clinical…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy (ISCT) Virtual Annual Meeting. The presentations provide details of Senti Bio’s…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?